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Abstract
apoE deficiency causes hyperlipidemia and premature ath-
erosclerosis. To determine if macrophage-specific expression
of apoE would decrease the extent of atherosclerosis, we
expressed human apoE in macrophages of apoE-null mice
(apoE-'-) and assessed the effect on lipid accumulation in
cells of the arterial wall. Macrophage-specific expression of
human apoE in normal mice was obtained by use of the
visna virus LTR. These animals were bred with apoE-'-
mice to produce animals hemizygous for expression of hu-
man apoE in macrophages in the absence of murine apoE
(apoE -'-,hTgE '°). Low levels of human apoE mRNA were
present in liver and spleen and high levels in lung and perito-
neal macrophages. Human apoE was secreted by peritoneal
macrophages and was detected in Kupffer cells of the liver.
Human apoE in the plasma of apoE-'-,hTgE+'° mice (n
= 30) was inversely correlated (P < 0.005) with the plasma
cholesterol concentration. After 15 wk on a normal chow
diet, atherosclerosis was assessed in apoE-'-,hTgE+'° ani-
mals and in apoE-'-,hTgE°'° littermates matched for
plasma cholesterol level (- 450 mg/dl) and lipoprotein pro-
file. There was significantly less atherosclerosis in both the
aortic sinus and in the proximal aorta (P < 0.0001) in the
animals expressing the human apoE transgene. In apo-
E-'-,hTgE+10 animals, which had detectable atherosclerotic
lesions, human apoE was detected in the secretory apparatus
of macrophage-derived foam cells in the arterial wall. The
data demonstrate that expression of apoE by macrophages
is antiatherogenic even in the presence of high levels of
atherogenic lipoproteins. The data suggest that apoE pre-
vents atherosclerosis by promoting cholesterol efflux from
cells of the arterial wall. (J. Clin. Invest. 1995. 96:2170-
2179.) Key words: apoE deficiency * atherogenesis * hyper-
lipidemia * lipoproteins * transgenic mice
Introduction
apoE is a 34,000-molecular weight protein that plays a central
role in maintaining plasma cholesterol homeostasis (1). apoE
Address correspondence to Robert E. Pitas, The Gladstone Institutes,
P. 0. Box 419100, San Francisco, CA 94141-9100. Phone: 415-826-
7500; FAX: 415-285-5632. Stefano Bellosta's current address is Insti-
tute of Pharmacological Science, University of Milan, Via Balzaretti 9,
20133 Milan, Italy.
Receivedfor publication 7 April 1995 and accepted in revisedform
4 August 1995.
mediates the binding of lipoproteins to the LDL receptor and
to the LDL receptor-related protein (1, 2), and it is required
for the clearance of chylomicron remnants, VLDL, intermediate
density lipoproteins, and a subclass of HDL from the plasma
(3-7).
The majority of plasma apoE is derived from the liver (8),
where it is synthesized primarily by hepatocytes (1). Apolipo-
protein E is also synthesized by macrophages in various tissues,
including Kupffer cells in the liver (9, 10). Apolipoprotein E
is abundant in both human and rabbit atherosclerotic lesions,
where it is produced by macrophages ( 11), but the role of apoE
in the atherosclerotic lesion and whether it is proatherogenic
or antiatherogenic are unknown. The apoE-mediated uptake of
lipoproteins by cells of the arterial wall may lead to lipid accu-
mulation and foam cell formation. Alternatively, apoE may
function in reverse cholesterol transport, contributing to the
removal of cholesterol from lipid-rich foam cells for delivery
to the liver (1, 12, 13). Support for both theories has been
obtained in in vitro studies.
Apolipoprotein E-null (apoE-'-) mice have been gener-
ated recently by gene targeting ( 14-16). These animals develop
pronounced hypercholesterolemia on a normal chow diet, with
a prominent increase in the level of VLDL and a decrease in
the level of HDL (15, 16). The mice develop foam cell-rich
fatty lesions in the aortic sinus and proximal aorta by 3 mo of
age ( 16, 17 ), and after 8-9 mo, fibrous lesions are present ( 17,
18). The atherosclerotic lesions in these mice have features
characteristic of those seen in humans and other species, includ-
ing both proliferating smooth muscle cells and calcium deposits
(17-22). These mice provide a unique model in which to test
the impact of cell-specific expression of apoE on atherogenesis.
Recent studies have addressed the role of apoE, produced
in the arterial wall by macrophages or other cell types, on the
development of atherosclerosis in mice. Linton et al. (23) have
reconstituted the expression of murine apoE by macrophages
after bone marrow transplantation in apoE-'- mice whose origi-
nal bone marrow was lethally irradiated. The expression of
murine apoE by macrophages both normalized plasma lipid
levels and prevented the normal development of atherosclerosis
seen in the apoE-deficient animals. Shimano et al. (24) gener-
ated transgenic mice that expressed human apoE in cells of
the arterial wall and in many other tissues of C57BL/6 mice.
Atherosclerosis was reduced in the transgenic animals even
though plasma lipid levels were not altered, suggesting that
enhanced production of apoE in these animals was antiathero-
genic (24). The results of these studies, however, do not define
the effect of macrophage-derived apoE on atherosclerosis. In
the study by Linton et al. (23), the marked reduction in plasma
cholesterol after bone marrow transplantation undoubtedly con-
tributed to the decrease in atherosclerosis, and in the study (24)
by Shimano et al., the reduction in lesion formation was due to
ectopic production of apoE by endothelial and smooth muscle
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Figure 1. Schematic representation of the human apoE gene construct
LTR-APOE, used to produce the transgenic mice expressing human
apoE in macrophages.
cells that do not normally express this apolipoprotein and by
the liver.
The aim of this study was to determine the effect of the
production of apoE by macrophages on the development of
atherosclerosis in transgenic mice. Human apoE expression was
directed to macrophages of murine apoE-'- animals, and the
effect on atherosclerosis was assessed. The expression of human
apoE in macrophages markedly reduced atherosclerosis in com-
parison to that observed in apoE-'-,hTgE0°0 littermates
matched for serum cholesterol levels and lipoprotein profile.
Our results demonstrate a direct protective effect of apoE on
arterial wall lipid accumulation that is independent of its plasma
lipid-lowering effects.
Methods
Production and screening of transgenic mice. Human apoE expression
was directed to macrophages by the sheep visna virus long terminal
repeat (LTR).' A fragment containing the LTR was generated from
the pVISLTRCAT construct, a gift of Janice Clements, Johns Hopkins
University, Baltimore, MD, described by Small et al. (25), by PCR
cloning. At the 5' end of the LTR, an oligonucleotide complementary
to 24 bases beginning 203 nucleotides upstream from the U3 element
of the LTR (26) was prepared. Extra sequences for Sall and ClaI
restriction endonuclease recognition were included at the 5' terminus
of the primer. At the 3' end of the LTR, an oligonucleotide complemen-
tary to 24 nucleotides that terminates 8 nucleotides downstream from
the U5 element of the LTR (27) was prepared. The sequence for AatH
recognition was included at the 3' terminus of the primer. The PCR-
cloned LTR (containing 622 nucleotides of viral sequence) was ligated
to the Aatll site in the first exon of the complete human apoE gene (3.6
kb in length), followed by 1.7 kb of 3' flanking sequence that terminated
at a HindEll site. The completed construct was inserted into the poly-
linker of pBSSK (Stratagene Inc., La Jolla, CA) at its SalI and Hindu
sites for subsequent DNA preparation. A map of the pLTR-APOE ex-
pression vector is presented in Fig. 1. A 5.9-kb fragment of LTR-
APOE was cut with SalI and HindIIl, electrophoresed on an agarose
gel, purified from the gel by electroelution, and injected into pronuclei
of one-cell ICR mouse embryos, as described (28). Transgenic founder
pups were identified by Southern blotting of tail-tip DNA (28, 29).
One of the founders that expressed significant quantities of human apoE
in macrophages was used to develop a transgenic line for the breeding
studies.
To generate the study population, murine apoE-null mice (apo-
E-'-) (C57BL/6 X 129/J hybrids), provided by Dr. N. Maeda (Univer-
sity of North Carolina, Chapel Hill, NC) (14, 16), were crossed with
transgenic ICR mice homozygous for the expression of human apoE in
macrophages (hTgE+'+). The F1 mice, which were hemizygous for the
human apoE transgene and heterozygous for the knockout mutation
1. Abbreviation used in this paper: LTR, long terminal repeat.
(apoE+'-,hTgE+'0) after this initial cross, were backcrossed to apoE-
null mice. Theoretically, 25% of the F2 progeny should lack mouse
apoE (apoE-'-) and be hemizygous for the human apoE transgene
(hTgE+'0). These F2 animals then were intercrossed to obtain mice
homozygous for the absence of murine apoE and hemizygous for the
human transgene (apoE--,hTgE '0) or homozygous (apoE ' ,hTgE '
+) for the expression of human apoE by macrophages. Thus, mice used
in this study were genetic hybrids of strains C57BL/6, 129/J, and ICR.
Mice were genotyped by Southern blotting. The mice were fed normal
laboratory mouse chow diet (Purina 5058; Ralston Purina Co., St. Louis,
MO) containing 9% fat and 0.02% cholesterol.
Southern blot analysis. Tail-tip DNA was purified (28), digested
with EcoRI, electrophoresed on a 1% agarose gel, transferred to nitro-
cellulose, and hybridized with a 32P-labeled human apoE cDNA probe
(29). Intact copies of the human apoE transgene were indicated by the
presence of a 1.9-kb band. Genotyping of apoE-null mice was as de-
scribed (14).
RNase protection assay. The expression of the transgene by macro-
phages was confirmed by RNase protection assay and Western blotting
(23, 30). Total RNA was extracted from mouse tissues and macrophages
using the Totally RNA Kit (Ambion Inc., Austin, TX). A 192-base
antisense RNA probe for human apoE mRNA was transcribed, using
bacteriophage T3 RNA polymerase in the presence of [32P]UTP, from
a human apoE cDNA fragment (corresponding to bases 217-411 of
the human apoE cDNA) that had been cloned in Bluescript vector
(Stratagene Inc.), as described (31 ). Hybridization of 5 Mg of the tissue
RNA with 2 x 105 cpm of labeled probe was carried out using the
Ribonuclease Protection Assay Kit II (Ambion Inc.). The protected
fragments were analyzed on 6% polyacrylamide gels containing 8 M
urea. The gels were dried and exposed overnight to photographic film
at -70°C. RNA from the human hepatoma cell line HepG2 served as
a positive control, and RNA from an apoE-'-,hTgE0°0 mouse served
as a negative control. As a control for the integrity of the RNA and to
ensure equivalent concentrations, 1 ig of total RNA from each organ
was subjected to 1% agarose gel electrophoresis and stained with ethid-
ium bromide.
Immunocytochemistry. Immunolocalization of apoE in macrophages
was achieved by indirect immunofluorescence. Briefly, peritoneal mac-
rophages were harvested from thioglycolate-stimulated mice by perito-
neal lavage with PBS and adhered to poly-L-lysine-coated slides for
30 min. All steps in the following protocol were carried out at room
temperature unless otherwise specified. The slides with adherent macro-
phages were gently rinsed in PBS and then fixed overnight at 4°C with
3% paraformaldehyde in PBS. After two 5-min washes in PBS, the
macrophages were permeabilized for 4 min in PBS containing 0.1%
Triton X-100. Excess aldehyde was quenched for 10 min with 0.05 M
ammonium chloride and nonspecific binding sites blocked for 30 min
with 3% BSA in PBS. The primary antibody, rabbit antiserum against
human apoE diluted 1:1,000 in PBS containing 1% BSA, was incubated
with the cells for 45 min. The slide was washed and exposed for 45 min
to secondary antibody, FITC-conjugated goat anti-rabbit IgG (Zymed
Laboratories, Inc., South San Francisco, CA) at 10 mg/ml in PBS with
1% BSA. Slides were washed, and macrophages were coverslip-
mounted using DABCO (2.3% 1,4-diazobicyclo-(2,2,2)-octane) in
PBS containing 90% glycerol. Images were captured by laser-scanning
confocal microscopy using the BHS filter block (excitor 488DF10, di-
chroic 51OLP, emission 515LP) on the MRC-600 system (Bio-Rad,
Hercules, CA).
For immunolocalization of apoE and macrophages in tissue sections,
mice at 15 wk of age were euthanized and perfusion-fixed with 3%
paraformaldehyde in PBS. The tissues were excised and snap-frozen in
liquid nitrogen prior to embedding in Tissue-Tek OCT compound
(Miles, Inc., Elkhart, IN). Frozen sections were cut on a Reichert 2800
cryostat (Reichert Scientific Instruments, Buffalo, NY). Once adhered
to slides, sections were immunostained for apoE as detailed above for
isolated macrophages.
Macrophages were detected in adjacent serial sections of atheroscle-
rotic lesions by immunolocalization of F4/80 antigen, a sensitive and
specific marker for mature murine macrophages (32). Nonpermeabil-
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ized cryostat sections were washed twice with PBS, once with 0.05 M
ammonium chloride for 10 min, and incubated for 30 min in PBS
with 3% BSA. The rat monoclonal antibody F4/80, against a plasma
membrane glycoprotein in murine macrophages (BioSource Interna-
tional, Camarillo, CA), was diluted 1:20 in PBS-glycine containing 1%
BSA and incubated with the sections overnight at 40C. The slides were
washed and then exposed for 1 h at 370C to biotinylated sheep anti-
rat Ig (Amersham Corp., Arlington Heights, IL) diluted 1:200 in PBS-
glycine containing 5% normal goat serum and 1% BSA. Slides were
washed exhaustively before incubation for 1 h at 370C with fluorescein-
labeled streptavidin (Amersham Corp.) diluted 1:2,500 in PBS-glycine
containing 1% BSA. Thereafter, slides were prepared for confocal mi-
croscopy as described for the immunocytochemistry of human apoE.
Tissues were examined using the GHS filter block (excitor 514DF10,
dichroic DR54OLP, emission 550LP) with the MRC-600 laser scanning
confocal microscope.
Expression of apoE by macrophages in culture. Mice were given a
3-ml intraperitoneal injection of 4% thioglycolate in water. After 3 d,
macrophages were harvested by peritoneal lavage with PBS, plated at
a density of 3.0 x 106 cells/35-mm dish, and allowed to adhere to
dishes for 3 h in DME containing 10% fetal bovine serum. The cell
monolayers were washed three times with serum-free DME and incu-
bated for 24 h with DME containing 10% fetal bovine serum, and then
for an additional 24 h in DME containing 0.2% BSA.
The media from the second 24-h incubation were collected, and,
after 100 ag/ml of phenylmethylsulfonyl fluoride and 5 ag/ml of leu-
peptin were added, centrifuged to eliminate suspended cells. To precipi-
tate the secreted apoE, fumed silica (Sigma Chemical Co., St. Louis,
MO) was added to the conditioned media (final concentration 1.5 mg/
ml) and centrifuged at 13,000 g for 10 min (30). Each pellet was
washed three times with sterile water and dissolved in gel-loading buffer
containing 2-mercaptoethanol. Samples were electrophoresed on 5-20%
polyacrylamide gradient gels containing SDS, as previously described
(30). Proteins were transferred to nitrocellulose paper by semidry blot-
ting (30) and incubated with either anti-human apoE or anti-mouse
apoE polyclonal antisera ( 1:1,000 dilution) raised in rabbit (generously
provided by Dr. K. H. Weisgraber, Gladstone Institute of Cardiovascular
Disease, San Francisco, CA). The bound primary antibodies were de-
tected using donkey anti-rabbit secondary antibody conjugated to horse-
radish peroxidase (1:5,000 dilution) (Amersham Corp.) and an En-
hanced Chemiluminescence kit (Amersham Corp.), according to the
manufacturer's instructions. The amount of apoE secreted by the cells
was quantitated by densitometric scanning (Ambis Scanner, San Diego,
CA) using standards of authentic human or mouse apoE electrophoresed
on the same gel (33).
Lipid and lipoprotein analyses. Analyses were performed on lit-
termates after a 4-h fast. Blood was drawn into tubes containing EDTA.
Plasma cholesterol and triglyceride concentrations were measured using
Boehringer-Mannheim Biochemicals (Indianapolis, IN) enzymatic
assay kits (34). Plasma human apoE concentration was measured by
Western blotting. 2 itl of plasma were electrophoresed on 5-20% poly-
acrylamide gradient gels containing SDS. The proteins were then trans-
ferred to nitrocellulose paper and the amount of apoE measured, as
described above. Purified human plasma apoE was used as a standard
for quantitation (33).
To determine the plasma lipoprotein profile, 100 ,ul of plasma was
applied to a Superose 6 column (FPLC system, Pharmacia, Uppsala,
Sweden) and eluted with 1 mM EDTA in PBS, pH 7.4, at a constant
flow rate of 0.4 ml/min (34, 35). Fractions (0.5 ml) were collected
and cholesterol and triglyceride concentrations measured enzymati-
cally (34).
Lesion area measurement. After a 4-h fast, 15-wk-old mice were
anesthetized with Metofane (methoxyflurane) (Pitman-Moore, Inc.,
Mundelein, IL). After perfusion fixation with 10% neutral buffered
formalin, the heart, together with the thoracic aorta, was removed from
the animals and processed as previously described (36). Sections were
stained with Oil Red 0, and lesions were quantified using the computer-
ized system, Image I (36).
Human
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Figure 2. Ribonuclease protection assay showing the expression of hu-
man apoE mRNA in tissues of transgenic mice. Total RNA was isolated
from the indicated tissues of mice that were homozygous for the apoE
knockout mutation and had the indicated genotype for the human apoE
transgene. Total RNA from the human hepatoma cell line HepG2 served
as positive control.
Results
Production and characterization of transgenic animals.
Transgenic mice expressing human apoE in macrophages were
produced by expressing apoE under the control of the visna
virus LTR, which has been used previously to direct the expres-
sion of a reporter gene specifically in macrophages of transgenic
mice (25). Each animal possessed one copy of the human apoE
gene. To determine the effect of macrophage expression of apoE
on serum lipid levels and on the development of atherosclerosis,
these animals homozygous for the human apoE transgene
(hTgE+'+) were crossed with murine apoE-null mice (apo-
E-'-), which develop spontaneous hypercholesterolemia and
atherosclerosis on a normal chow diet (15, 16). The progeny
were backcrossed to the apoE-null mice to produce mice (25%)
that did not express murine apoE but were hemizygous for the
expression of human apoE by macrophages (apoE-'-,hTgE+'0).
These animals were then intercrossed. The litters obtained from
this final mating contained apoE-null mice that did not express
human apoE (apoE-'-,hTgE0'0, which were used as control
mice) and mice hemizygous (apoE--,hTgE+'0) or homozy-
gous (apoE-'-,hTgE+'+) for the expression of human apoE by
macrophages.
Sites of apoE production in mice were detected using RNase
protection assays and immunofluorescence microscopy. All of
the animals lacked mouse apoE mRNA, and all of the control
apoE-'-,hTgE°'° mice lacked human apoE (Fig. 2). Human
apoE mRNA was detected at relatively high levels in peritoneal
macrophages and lung and at lower levels in the liver and spleen
of the apoE-'-,hTgE+'° and apoE-'-,hTgE+'+ animals but not
in the apoE-'-,hTgE°'° mice (Fig. 2). As expected, the mice
homozygous for the human transgene showed an increased sig-
nal as compared with that seen in mRNA from hemizygous
animals.
Macrophage production of human apoE was confirmed by
immunocytochemistry. Intense immunoreactivity for human
apoE was detected in peritoneal macrophages from the
transgenic animals but not in control macrophages (Fig. 3). The
apoE was present as intense unipolar juxtanuclear fluorescence,
which represents apoE in the Golgi apparatus, indicating that
apoE is a secreted protein (Fig. 3, A and B). To a lesser extent,
apoE immunolocalized in a cytoplasmic punctate pattern may
represent apoE in secretory vesicles or endosomes (Fig. 3).
The level of secretion of human apoE by mouse peritoneal
macrophages was examined directly by analysis of conditioned
medium from the cells on Western blots. The macrophages from
the mice expressing the human apoE (apoE-'-,hTgE+'° and
apoE-'-,hTgE+'+) secreted low levels of apoE compared to
the amount of apoE secreted from the macrophages of a non-
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Figure 3. Confocal fluorescence microscopy showing the expression of
human apoE by macrophages from apoE-'-,hTgE+'° (A) and apo-
E-'-,hTgE+'+ mice (B) and the lack of expression by macrophages
obtained from apoE-'- ,hTgE°'° mice (C), which were used as negative
controls. Indirect immunofluorescence was performed with an antibody
specific for human apoE as described in Methods. Note the unipolar
juxtanuclear fluorescence, indicative of apoE immunolocalization in the
Golgi apparatus and endoplasmic reticulum. The punctate cytoplasmic
fluorescence may be endosomal or from secretory vesicles. (Bar = 10
ym and refers to all figures.)
transgenic C57BL/6 mouse. The human apoE secreted was 3-
8% of the level of mouse apoE (Table I), and it comigrated
with authentic human apoE by electrophoresis on polyacryl-
amide gels (data not shown).
Table L Secretion of apoE from Mouse Peritoneal Macrophages
apoE secreted*
Mouse Human
,ig/mg of cell proteint
C57BL/6 (nontransgenic) 2.06
apoE-',hTgE"'- 0.06
apoE-JhTgE+"° 0.13
apoE-'-,hTgE+'+ 0.16
apoE`',hTgE+'+ 0.16
* Cells were isolated from thioglycolate-stimulated animals and incu-
bated for 24 h at 370C in DME containing 0.2% BSA. The medium
was then collected, and the amount of apoE secreted was measured as
described in Methods. t Each value is the mean of two separate experi-
ments. The duplicates did not differ by more than 10%.
The visna virus LTR has previously been reported to direct
the expression of a reporter construct both by macrophages and
by spleen lymphocytes (25). We prepared spleen lymphocytes
as described (25) and examined the medium for the presence
of apoE. In two independent experiments using spleens from
two animals that expressed apoE in peritoneal macrophages, we
did not detect expression of apoE by lymphocytes.
The tissue distribution of the human apoE mRNA in lung
and spleen is consistent with macrophage expression. In the
liver, human apoE was detected by immunocytochemistry in
individual cells present in the sinusoids, suggesting by their
pattern and location that they were Kupffer cells (data not
shown). However, a low level of hepatocyte expression could
not be ruled out. The apoE was not detected in sinusoidal endo-
thelial cells.
Effect of human apoE on lipids and lipoprotein profile in
apoE-null mice. To determine the impact of the secretion of
human apoE by the macrophages on plasma lipid levels, blood
was drawn from 15-wk-old mice, and total plasma cholesterol
and triglyceride levels were determined. The expression of hu-
man apoE by macrophages reduced plasma cholesterol levels
substantially, in a gene dose-dependent manner (Table HI). By
Table II. The Effect of Expression of Human apoE by
Macrophages on Plasma Cholesterol and Triglyceride
Concentrations in Murine apoE-null Mice
Plasma*
Mice Cholesterol Triglycerides
mg/dlt
apoE-',hTgE°'° (n = 31) 593±157 194±108
apoE-',hTgE+/' (n = 39)§ 408±12611 184±125
apoE-',hTgE+'+ (n = 7)§ 236±98111 144±60
* Blood was drawn from 15-wk-old mice after a 4-h fast. Plasma choles-
terol and triglyceride levels were measured as described in Methods.
Data are reported as the mean±SD for the number of animals indicated.
The animals heterozygous and homozygous for expression of human
F g i marp agdc express murine apoE. Theani l we
generated as described in Methods. 11 P < 0.01 vs apoE'-,hTgE".
p < 0.025 vs apoE-',hTgE+'°.
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Table III. Plasma Cholesterol and Triglyceride Concentrations of
Mice* that Were Used to Examine the Development
ofAtherosclerosis
Plasmat
Mice Cholesterol Triglycerides
mg/dl§
apoE-',hTgE° (n = 15) 482±62 173±67
apoE-',hTgE"'0 (n = 13)II 449±70 153±54
0* N * Apolipoprotein E-null mice and littermates hemizygous for the ex-
* pression of human apoE in macrophages. * Plasma was obtained from
0 _ 15-wk-old animals fasted for 4 h and lipid determinations performed as
described in Methods. § The data are reported as the mean±SD. 11 The
III I
animals expressing human apoE in macrophages did not express murine
0 2 4 6 8 10 12 apoE, as described in the legend to Table I and in Methods.
Plasma ApoE (jig/ml)
Figure 4. Inverse correlation between plasma cholesterol levels and
plasma human apoE concentration in apoE-'-,hTgE"'0 mice expressing
human apoE in macrophages. Plasma cholesterol and human apoE con-
centrations in 15-wk-old mice were measured on blood obtained after
a 4-h fast, as described in Methods. r2 = 0.668, P < 0.005 using a one-
tailed test.
comparison to apoE-null littermate controls apoE-'-,hTgE010
(not expressing human apoE), plasma total cholesterol levels
in apoE-'-,hTgE"'0 animals were reduced by 31%, whereas
in the apoE-'-,hTgE"'+ mice, the levels dropped by 60%.
There was no effect of expression of human apoE on plasma
triglyceride concentrations in the apoE-'-,hTgE"'0 animals or
in the apoE-'-,hTgE"'+ mice (Table II).
To determine if the reduction in plasma cholesterol levels
was directly proportional to the amount of human apoE in the
plasma, the plasma apoE concentration was determined in 30
apoE-'-,hTgE+'0 mice. In these animals, human apoE in the
plasma varied from 0.2-11.0 jig/ml and plasma cholesterol
from 200-650 mg/dl. There was a clear inverse relationship
between the concentration of apoE and plasma cholesterol lev-
els, P < 0.005 (Fig. 4). Animals with the highest plasma apoE
concentration had the lowest plasma cholesterol. As expected,
none of the animals had any detectable mouse apoE in their
plasma (data not shown). The reason for the wide range in
plasma apoE levels is unknown; however, it is likely to result
from the genetic heterogeneity of the animals.
Effect of human apoE production on atherosclerosis in
apoE-null mice. We considered that apoE production by macro-
phages might result in reduced lipid deposition in the arterial
wall of the apoE-null mice. To explore this postulate, we exam-
ined the extent of atherosclerosis in 15 apoE-'-,hTgE0'° mice
(eight females and seven males) not expressing human apoE
and in 13 apoE-'-,hTgE+'0 mice (six females and seven males)
that were selected on the basis of similar levels of total plasma
cholesterol (Table III). The plasma cholesterol concentrations
in the apoE-'-,hTgE0'0 mice selected for the atherosclerosis
study ranged from 325 to 555 mg/dl and, in the apo-
E',hTgE+'° mice, from 334 to 551 mg/dl. The plasma level
of human apoE in the apoE-'-,hTgE+'0 mice studied ranged
between 2 and 4 ag/ml, which is < 7% of the level of the
normal mouse plasma apoE concentration (60-80 ag/ml) (37).
The animals were maintained for 15 wk on a normal labora-
tory chow diet. The plasma lipoprotein profiles in the apo-
E-'-,hTgE°'° mice and the apoE-'-,hTgE+'0 animals were ex-
amined by FPLC. A comparison of the elution profiles of the
two groups is shown in Fig. 5. The distributions of plasma
cholesterol (Fig. 5 A) and triglyceride (Fig. 5 B) among the
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the symbols are the plasma cho-
lesterol concentration (mg/dl) for
individual animals. The lesion
areas for some of the animals are
clustered, and therefore choles-
terol values could not be reported
in the figure. The cholesterol val-
C ues for these mice are: cluster a,
423, 535, 473, 362,482,405, 461,
and 449 mg/dl; cluster b, 394,
470, 438, 545, and 325 mg/dl;
cluster c, the same as cluster a,
with the addition of four other animals with plasma cholesterol levels of 453, 551, 549, and 486 mg/dl. The mean lesion area values per section
for the entire aortic root, for the sinus, and for the proximal aorta were 13,600±800; 20,600±1,200; and 2,900±300 ,m2 in the apoE-'-,hTgE0'°
animals and 4,800±500; 7,700±800; and 40±20 1m2 in the apo-E-'-,hTgE"'0 animals hemizygous for expression of human apoE in macrophages
(P < 0.0001). The areas are reported as tim2±SEM. The horizontal lines represent the mean value of lesion area for each group of mice.
plasma lipoprotein fractions were essentially superimposable.
The concentrations of cholesterol in VLDL (fractions 16-19)
and HDL (fractions 29-35) in the apoE-'-,hTgE010 (control)
animals were 360±60 and 42±14 mg/dl, respectively. In the
apoE-'-,hTgE"'0 animals, the VLDL and HDL cholesterol lev-
els were 328±44 and 48±11 mg/dl, respectively. Thus, the
low-level expression of human apoE by macrophages did not
appreciably influence the plasma lipoprotein distribution in the
animals selected for the atherosclerosis study.
To determine whether the secretion of human apoE by mac-
rophages could protect against the deposition of lipids and foam
cell formation in the arterial wall, the extent of atherosclerosis
in the aortic sinus and proximal aorta was determined in 43 Oil
Red 0-stained sections from each of the animals (Fig. 6)
using a quantitative assay. The apoE-'-,hTgE"'0 animals had
significantly (P < 0.0001 ) less atherosclerosis than the control
apoE-'-,hTgE0'0 animals, whether the data were compared for
the entire aortic root (Fig. 6 A), for the aortic sinus (Fig. 6
A), or for the proximal aorta (normally quantitated in murine
atherosclerosis studies) (Fig. 6 B). The mean lesion area values
per section for the total region examined, the sinus, and the
proximal aorta for the apoE-'-,hTgE0'0 animals were
13,600+800 (±SEM) pm2, 20,600+1,200 ym2, and
2,900±300 gum, respectively. In the apoE-'-,hTgE+'0 animals,
these values decreased dramatically to 4,800±500, 7,700±800,
and 40±20 IMm2, respectively. Both groups of mice have the
same genetic background, C57BL/6 x 129/J x ICR.
The extent of atherosclerosis also was compared in male
and female mice. The female mice had more extensive athero-
sclerotic lesions than male littermates. The extent of atheroscle-
rosis was significantly reduced in both male and female animals
by expression of human apoE. In the males, the mean lesion
area for the aortic root was 11,500±1,000 (±SEM) pm2 in the
apoE-'-,hTgE°'0 and 1,100±200 ,um2 in the apoEl',hTg-
E+'0 (P < 0.0001). In the females, the mean lesion area was
15,500±1,300 HIm2 in the apoE`,hTgEO'° and 9,000±1,000
,Im2 in the apoE',hTgE+'0 (P < 0.0002).
To verify that human apoE was produced in the arterial
wall, sections of aorta from transgenic animals with significant
lesions were analyzed for the presence of human apoE by immu-
nocytochemistry (Fig. 7). Human apoE was clearly detectable
in foam cells present within the lesions of the apoE',hTg-
E+'° transgenic animals (Fig. 7, A-C) but not in lesions from
the control apoE',hTgE0'0 mice (Fig. 7 D). The lesions in the
animals hemizygous for expression of human apoE consisted of
fatty streaks with no fibrous caps. Apolipoprotein E-expressing
foam cells were seen at the bases of the valve commisures (Fig.
7, A and B) and occasionally were observed below the internal
elastic laminae (Fig. 7 B). The lesions in apoE-'-,hTgE010
mice were more advanced and widespread, had early fibrous
capping, and contained necrotic cells and other debris.
Foam cells in these atherosclerotic lesions are primarily of
macrophage origin. To verify that human apoE was produced by
macrophages in the fatty lesions in apoE` ,hTgE+'0 transgenic
mice, serial sections of the same lesion were immunostained
for the presence of human apoE (Fig. 8, A and B) or for the
presence of murine macrophages (Fig. 8, C and D). Human
apoE was immunolocalized in lesion foam cells (Fig. 8, A and
B) in a pattern similar to that shown in Fig. 7. The underlying
cells of the tunica media were not stained. The next serial sec-
tion (panels A and C and panels B and D are consecutive serial
sections) shows macrophage-specific staining in the same area
in which apoE was expressed, demonstrating that the macro-
phages are the most likely source of the apoE. There is some
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Figure 7. Expression of human apoE by foam cells present in the lesion areas. Immunofluorescent images showing the presence of apoE atherosclerotic
lesion macrophages from apoE-'-,hTgE"'0 mice (A-C) and the lack of expression in an atherosclerotic lesion from an apoE-'-,hTgE0'° mouse
(D). Cryostat sections from near the beginning of the proximal aorta were stained by indirect immunofluorescence cytochemistry using an antibody
specific for human apoE. An FITC-conjugated secondary antibody was used to detect the primary antibody. Confocal immunofluorescence microscopy
was used to image (2 pm) optical sections of the lesions. (A) An apoE-containing fatty streak including several foam cells. (B) A similar fatty
streak with the nuclei of the foam cells clearly resolved. Note the apoE-positive cells beneath the internal elastic lamina (running between the
arrows). (C) Several macrophage-derived foam cells that are expressing human apoE, shown at a higher magnification. Note the polar juxtanuclear
(arrow) and perinuclear fluorescence in the cell indicated by the arrow. This pattern of fluorescence indicates the presence of apoE in the secretory
apparatus (Golgi apparatus and endoplasmic reticulum) of the cell. (D) An atherosclerotic lesion from an apoE-'-,hTgE0'0 mouse, shown as a
negative control. As expected, human apoE is not detected in this section. This is the negative control for A and B. Background fluorescence reveals
the histology of the intimal lesion and part of the tunica media. (Bars = 10 ptm.)
apoE that appears to be extracellular and associated with the
matrix. The data therefore indicate the production of human
apoE by macrophages in the arterial wall. Expression of human
apoE in atherosclerotic lesion macrophages suggests that the
production of apoE by these macrophages could contribute to
the reduced lesion development noted in these animals.
Discussion
In this study, we have demonstrated that the expression of hu-
man apoE by macrophages reduced atherosclerosis in apoE-null
mice despite the persistence of hypercholesterolemia. Human
apoE was expressed in macrophages of transgenic animals, and
they were cross-bred with murine apoE-'- mice to develop
progeny that did not express murine apoE (apoE-'-) but were
homozygous (apoE-'-,hTgE+'+) or hemizygous (apo-
E-'-,hTgE+'°) for expression of human apoE in macrophages.
Atherosclerosis was assessed in chow-fed 15-wk-old apo-
E-'-,hTgE+'° mice and in apoE-'-,hTgE°'° littermates
matched for plasma cholesterol concentration and lipoprotein
profile. The data clearly demonstrate that the expression of hu-
man apoE in macrophages, in the absence of murine apoE,
reduced atherosclerosis by 63 and 98% (P < 0.0001) in the
aortic sinus and proximal aorta, respectively.
Macrophage-specific expression was obtained using a con-
struct that contained a 5.3-kb segment of the apoE gene under
transcriptional control of the visna virus LTR. This promoter
element previously had been shown to direct macrophage ex-
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Figure 8. Sequential cryostat sections of an atherosclerotic lesion from the proximal aorta of an apoE-'-,hTgE"'0 transgenic mouse showing
colocalization of immunofluorescence staining for human apoE (A and B) and murine macrophages (C and D). Panels A and C and panels B and
D show consecutive cryostat sections immunolabeled to detect apoE and a macrophage-specific antigen, respectively. Macrophage-specific staining
is observed in the same area of the lesion and, in some cases in the same cells, as expression of human apoE. (Bar = 10 jtm for both panels.)
pression of a chloramphenicol acetyltransferase reporter con-
struct in transgenic animals (25). A transgenic mouse line ex-
pressing human apoE in macrophages was established. These
animals were crossed with murine apoE-null mice to create
transgenic mice lacking mouse apoE and producing human
apoE predominantly in macrophages. Peritoneal macrophages
from these animals secreted human apoE, and human apoE was
detected in macrophage-derived foam cells in atherosclerotic
lesions. The apoE mRNA tissue distribution in the liver, lung,
and spleen is consistent with macrophage production. In the
liver, Kupffer cells appeared to be responsible for the production
of human apoE, although a low level of expression by hepato-
cytes cannot be ruled out.
Interestingly, the expression of human apoE in macrophages
resulted in low, but significant, levels of apoE in the plasma.
The concentration of human apoE in the plasma of 30 apo-
E-'-,hTgE+'0 animals ranged from 0.2 to 11 jg/ml, much
lower than the level of murine apoE normally present in non-
transgenic animals (37). The plasma cholesterol concentration
was inversely related to the amount of human apoE present in
the plasma. Presumably, the entry of even small amounts of
apoE into the plasma of the apoE-1-,hTgE+'0 animals reduces
the hyperlipidemia by mediating clearance of chylomicron and
VLDL remnants, principally by hepatic receptor pathways. This
hypothesis is supported by the finding that expression of rat
apoE in transgenic mice reduces plasma cholesterol levels (38-
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40), as does the infusion of apoE into Watanabe heritable hy-
perlipidemic rabbits that are normally hypercholesterolemic (6,
41). Our results also are consistent with the recent work of
Linton et al. (23), in which apoE expression was established
in apoE-'- animals by bone marrow transplantation, leading to
a normalization of plasma lipid levels. However, the bone mar-
row transplant experiments showed a greater effect on suppres-
sion of plasma cholesterol than that observed in our studies.
This enhanced effect on suppression of cholesterol levels proba-
bly was due to a higher level of apoE expression by the trans-
planted murine macrophages than the level of expression of the
human apoE transgene obtained in our studies. In fact, we have
shown that the level of secretion of human apoE by murine
apoE-'-,hTgE+'0 macrophages is only 3-8% of the level of
murine apoE secreted by normal macrophages. Alternatively,
the murine apoE could be more effective in facilitating the
clearance of mouse lipoproteins than human apoE, or the differ-
ent genetic background of the mice used in our study could
explain the different effect on plasma cholesterol.
The reduction of plasma lipoprotein levels alone could result
in a reduction in the extent of atherosclerotic lesions. However,
due to the wide variation in plasma cholesterol levels in the
transgenic animals, we were able to select apoE-'-,hTgE010
animals and apoE-'-,hTgE+'0 littermates that possessed equiv-
alent plasma cholesterol levels for evaluation of the effect of
apoE expression by macrophages on accumulation of lipid in
macrophage-derived foam cells in the arterial wall. The two
groups of animals had similar lipoprotein profiles and nearly
identical plasma concentrations of VLDL and HDL. Nonethe-
less, the apoE-'-,hTgE+'0 animals did not develop significant
atherosclerotic lesions in their proximal aorta, although their
plasma lipid levels (- 450 mg/dl) were sufficient to cause the
formation of extensive lesions in apoE-'-,hTgE010 littermates
(15, 16). In agreement with previous reports (36, 42, 43), we
also showed that female mice develop more extensive athero-
sclerosis than their male littermates in both the mice lacking
human apoE and the mice expressing human apoE. These stud-
ies demonstrate for the first time that macrophage-specific ex-
pression of apoE markedly retards atherosclerosis in hypercho-
lesterolemic animals independently of gross changes in circulat-
ing plasma lipoproteins. However, we cannot rule out the
possibility that the human apoE circulating in the plasma may
have an undetected effect on lipoprotein composition or metabo-
lism that could contribute to the reduced susceptibility to athero-
sclerosis. Our studies differ significantly from those recently
published by Linton et al., in which repopulation of previously
irradiated apoE-'- animals with bone marrow cells expressing
apoE resulted in total normalization of plasma lipid levels and
reduced atherosclerosis, as would be expected (23). Reduced
atherosclerosis also was observed recently in transgenic mice
expressing human apoE in a variety of tissues, including ectopic
expression by endothelial and smooth muscle cells (cells that
do not normally express apoE) of the arterial wall and in liver
(24). In these latter studies, the effect of macrophage produc-
tion of apoE could not be evaluated.
The mechanism by which the secretion of apoE by macro-
phages protects against the formation of atherosclerotic lesions
is unknown. It has been postulated that apoE-'- mice develop
atherosclerosis on a normal chow diet because of increased
plasma levels of VLDL and intermediate density (atherogenic)
lipoproteins and reduction in the plasma levels of HDL (antiath-
erogenic lipoproteins) (15, 16). In fact, two groups have re-
ported that expression of human apoA-I increases HDL levels
in apoE-null mice and reduces atherosclerosis (44, 45). In our
study, VLDL, LDL, and HDL levels in the apoE-'-,hTgE+'0
animals were equivalent to those of apoE-'-,hTgE010 mice,
indicating that the protective effect of apoE is most likely not
due to changes in plasma lipoproteins.
The protective effect of macrophage-derived apoE, there-
fore, may be due to an enhanced removal of cholesterol by
lipoproteins from the cells of the arterial wall. Previously we
have postulated a secretion-capture role for apoE (1). Apolipo-
protein E secreted from cells interacts with cholesterol-rich lipo-
proteins in the environment of the cells, and the apoE-enriched
particles participate in a local redistribution of the lipids to cells
requiring lipids, or in a more global redistribution, the apoE
targets the particles for receptor-mediated clearance (e.g., by
the liver). This hypothesis is supported by the recent studies
of Shimano et al. (24), in which enhanced efflux of cholesterol
from the aortic wall into plasma was observed in animals ex-
pressing apoE in endothelial cells and smooth muscle cells of
the arterial wall. In vitro studies have shown that secretion of
apoE by macrophages in the presence of HDL can stimulate
cholesterol efflux from cholesterol-enriched macrophages (46).
It is possible that the human apoE secreted by macrophages in
the arterial wall combines with HDL to form HDL enriched in
apoE, which facilitates cholesterol efflux, as previously de-
scribed (47-49). While plasma HDL levels are low, they may
be sufficient, in the presence of macrophage-derived apoE, to
mediate cholesterol efflux from macrophages and to be rapidly
cleared from the plasma. Alternatively, apoE alone may also
function in reverse cholesterol transport, as suggested by recent
studies of Assmann and associates (50). In these studies they
identified a plasma lipoprotein with y mobility, on agarose gels,
that contained only apoE. This lipoprotein is present in human
and normal mouse plasma, but it is absent in apoE-'- mouse
plasma. It is secreted by peripheral cells, probably macrophages,
and is a potent acceptor of cell-derived cholesterol (50). Addi-
tionally, apoE production by arterial wall macrophages may be
modifying cytokines or growth factor modulation or activity,
thus indirectly altering arterial wall foam cell formation. These
possibilities remain to be explored.
In summary, we have shown that the expression of human
apoE by macrophages is able to prevent the development of
atherosclerotic lesions in hypercholesterolemic mice. This study
demonstrates that only a low level of macrophage-specific ex-
pression of apoE, which is insufficient to have a significant
impact on plasma lipid levels and lipoprotein distribution, has
a highly significant impact on reducing atherosclerosis. These
data suggest that targeted expression of apoE production by
macrophages in the arterial wall could be a promising therapeu-
tic approach for reducing foam cell formation and atheroscle-
rosis.
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